M&A Deal Summary

InMed Pharmaceuticals Acquires BayMedica

On June 29, 2021, InMed Pharmaceuticals acquired life science company BayMedica

Acquisition Highlights
  • This is InMed Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is InMed Pharmaceuticals’ 1st transaction in the United States.
  • This is InMed Pharmaceuticals’ 1st transaction in Nevada.

M&A Deal Summary
Date 2021-06-29
Target BayMedica
Sector Life Science
Buyer(s) InMed Pharmaceuticals
Deal Type Add-on Acquisition

Target

BayMedica

Incline Village, Nevada, United States
BayMedica is a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable, and proprietary platform to produce high quality, rare cannabinoids for consumer applications and cannabinoid-derived new chemical entities for pharmaceutical applications. BayMedica is based in Incline Village, Nevada.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

InMed Pharmaceuticals

Vancouver, British Columbia, Canada
Category Company
Founded 1981
Sector Life Science
Employees13
Revenue 4M USD (2023)
DESCRIPTION

InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed Pharmaceuticals was formed in 1981 and is based in Vancouver, British Columbia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Nevada) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal